Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Mar 2015

Chen Eddy J, Sowalsky Adam G, Gao Shuai, Cai Changmeng, Voznesensky Olga, Schaefer Rachel, Loda Massimo, True Lawrence D, Ye Huihui, Troncoso Patricia, Lis Rosina L, Kantoff Philip W, Montgomery Robert B, Nelson Peter S, Bubley Glenn J, Balk Steven P, Taplin Mary-Ellen

Abstract excerpt

PURPOSE: The CYP17A1 inhibitor abiraterone markedly reduces androgen precursors and is thereby effective in castration-resistant prostate cancer (CRPC). However, abiraterone increases progesterone, which can activate certain mutant androgen receptors (AR) identified previously in flutamide-resistant tumors. Therefore, we sought to determine if CYP17A1 inhibitor treatment selects for progesterone-activated mutant...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Androstenes
Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Helicases

Share to Progesterone

Share to Prostatic Neoplasms, Castration-Resistant

Share to PTEN Phosphohydrolase

Share to Receptors, Androgen

Share to Steroid 17-alpha-Hydroxylase

Source

Open in PubMed Open full text

Identifiers

PMID: 25320358
DOI: 10.1158/1078-0432.CCR-14-1220
PMCID: PMC4359958

Genes

CHD1
PTEN

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors.PMID 25320358Read ↗

Molecular Profile Changes in Patients with Castrate-Resistant Prostate Cancer Pre- and Post-Abiraterone/Prednisone TreatmentSemantic proximity Read ↗

Treatment-dependent androgen receptor mutations in prostate cancer exploit multiple mechanisms to evade therapy.Semantic proximity Read ↗

A Clinically Relevant Androgen Receptor Mutation Confers Resistance to Second-Generation Antiandrogens Enzalutamide and ARN-509Semantic proximity Read ↗

5β-Dihydrotestosterone and mutant androgen receptor vulnerability in prostate cancerSemantic proximity Read ↗

An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide).Semantic proximity Read ↗

CYP17A1 polymorphism c.-362T>C predicts clinical outcome in metastatic castration-resistance prostate cancer patients treated with abiraterone.Semantic proximity Read ↗

A novel steroidal antiandrogen targeting wild type and mutant androgen receptors.Semantic proximity Read ↗

Overcoming mutation-based resistance to antiandrogens with rational drug design.Semantic proximity Read ↗

Common Genetic Variation in CYP17A1 and Response to Abiraterone Acetate in Patients with Metastatic Castration-Resistant Prostate Cancer.Semantic proximity Read ↗

Antiandrogens act as selective androgen receptor modulators at the proteome level in prostate cancer cells.Semantic proximity Read ↗

The association between missense polymorphisms in SRD5A2 and HSD3B1 and treatment failure with abiraterone for castration-resistant prostate cancer.Semantic proximity Read ↗

Re: Wnt-pathway Activating Mutations Are Associated with Resistance to First-line Abiraterone and Enzalutamide in Castration-resistant Prostate Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.